AstraZeneca Acquires Omniose for Vaccine Pipeline

AstraZeneca has acquired early-stage biotechnology firm Omniose to bolster its infectious diseases division. The deal integrates a proprietary bioconjugation platform to advance new bacterial vaccines.

Xurve View
Insights:
FILE PHOTO: An AstraZeneca sign is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo

ASTRAZENECA PLC acquired early-stage biotechnology firm Omniose on Tuesday to bolster its vaccine pipeline against serious bacterial infections. Financial terms of the undisclosed transaction remain confidential between the parties. The buyout follows a three-year exclusive research collaboration between the two drug developers.